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do the Editor: Male patients with Danon disease usually present in
dolescence with left ventricular hypertrophy (LVH) and a Wolff-
arkinson-White (WPW) pre-excitation pattern on electrocardio-
ram (ECG). The typical course involves deterioration to severe
entricular dysfunction with end-stage heart failure or sudden cardiac
eath. Histopathology of cardiac and skeletal muscle tissue displays
acuolar myopathy and lysosomal glycogen accumulation (1–3).
Characterization of the disease in female patients has been thus
ar limited. We present 3 families in which an initial diagnosis of
anon disease in a male proband revealed affected female family
embers who previously presented with a cardiomyopathy as
aving a dilated cardiomyopathy (DCM) phenotype. Some female
embers had been previously diagnosed with peri-partum cardio-
yopathy (PPCM). The use of ECG frequently did not demon-
trate pre-excitation, and heterogeneous histopathological findings
ere observed in the cardiac explant in those female patients who
ad undergone heart transplantation.
The clinical data of 3 families with Danon disease were
nalyzed. Patients were evaluated by history, physical examination,
CG, echocardiography, lysosomal-associated membrane protein
(LAMP-2) genetic analysis, and histopathological analysis. In
his study a DCM phenotype was defined as an echocardiographi-
ally derived left ventricular ejection fraction (LVEF) 45% with
ormal LV wall thicknesses and an echocardiographic left ventric-
lar end-diastolic dimension (LVEDD)2 SDs above the normal
ean for body surface area in patients 18 years of age (5) and
56 mm for patients18 years of age (6). We defined LVH as an
chocardiographically derived LV posterior and/or septal wall
hickness 2 SDs above the normal mean for body surface area in
atients 18 years of age (5) or 15 mm in patients 18 years of
ge (4), associated with a nondilated chamber.
Probands 1, 2, and 3 (Figs. 1A to 1C, P1, P2, P3, respectively)
resented at ages 15 years, 17 years, and 20 months with a WPW
attern on their ECGs and LVH (LV diastolic posterior wall
hicknesses of 18, 15, and 14 mm, respectively, on echocardiogram.
hese wall thicknesses were all4 SDs above the normal mean for
ody surface area). Cardiac biopsy revealed myocyte hypertrophy
ith extensive cytoplasmic vacuolization (a representative histol-
gy of proband 1 is shown in Fig. 1D). The use of LAMP-2 gene
equencing revealed 2 distinct, previously reported, mutations in
robands 1 and 2. A nucleotide G293A transition in exon 3 of the
AMP-2 gene was identified in proband 3. The later is a novel
utation that has not been previously reported but is predicted to
e pathogenic.
Male patients 4 and 5 (Fig. 1B II-6 and 1C III-5, respectively)
re maternal uncles of probands 2 and 3, who died suddenly at 17
nd 20 years of age, respectively. The presumed cause of their
eath per autopsy (no further information available) was hypertro-
hic cardiomyopathy (HCM). cMothers of probands 1 and 2 (Fig. 1A II-2 and 1B II-3,
espectively) presented in early adulthood (ages 24 and 34 years,
espectively) with heart failure. Proband 1’s mother developed
eart failure at the end of her first pregnancy. She was diagnosed
ith presumed PPCM (LV enlargement with severely decreased
ystolic function, estimated EF 20% to 25%). Her clinical status
mproved shortly after delivery but worsened in a subsequent
regnancy, progressing to severe heart failure and ultimately
eading to heart transplantation. The mother of proband 2 was
iagnosed with DCM (LVEDD of 66 mm, EF 25%). She
eteriorated rapidly, requiring heart transplantation at 19 months
fter presentation. Neither ECG demonstrated a WPW pattern.
istopathology of both explants showed marked myocyte hyper-
rophy and extensive interstitial fibrosis. Cytoplasmic vacuolization
as present but was heterogeneous in distribution (a representative
istology of proband 1’s mother is shown in Fig. 1E). LAMP-2
ene sequencing of proband 1’s mother revealed a LAMP-2
utation identical to her son’s mutation.
The mother of proband 3 (Fig. 1C, III-3) was diagnosed with
resumed HCM at age 14 years (diastolic interventricular septal
all thickness of 15 mm,9 SDs above the normal mean for body
urface area) when a screening echocardiogram was performed
ecause of sudden cardiac death in her maternal half-brother.
he has been treated with propanolol for occasional palpitations
ut has demonstrated neither heart failure nor a WPW pattern on
er ECG.
Proband 3’s maternal grandmother (Fig. 1C, II-2) died sud-
enly during pregnancy at the age of 28 and was diagnosed as
PCM (no further information available). Proband 1’s half sister
Fig. 1A, III-1) presented with a DCM phenotype (borderline
VEDD of 54 mm, LVEF of 42%), on a screening echocardio-
ram at the age of 20. An ECG did not demonstrate a WPW
attern. She developed rapidly progressive heart failure requiring
eart transplantation at 13 months after her initial diagnosis.
xplant histopathology was similar to that of her mother.
AMP-2 gene sequencing revealed the same LAMP-2 mutation
hat her mother and brother carry. Testing of her maternal
randmother (Fig. 1A, I-1) was negative, signifying a de novo
utation in her mother.
Proband 2’s maternal aunt (Fig. 1B, II-7) was diagnosed with
PW and underwent ablation. She has no other known cardiac
bnormalities. Proband 2’s maternal grandmother (Fig. 1B, I-1)
ied of a cardiac cause (further history is unavailable) at the age of
5 years.
We describe 3 families demonstrating heterogeneous clinical
henotypes in female members with LAMP-2 mutations. This
eterogeneity may be attributed to a variable genotype-
henotype relationship of different mutations. The phenotypic
ifference between male and female subjects with Danon
ardiomyopathy is presumably the gene dosage difference (2,3).
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January 26, 2010:408–13evere female cases can be attributed to X chromosome inac-
ivation of nonmutated chromosome (unfavorable lyonization),
eaving only mutated LAMP-2 protein (1). Random variable X
nactivation may account for the differences in phenotypic
everity between female members in the same family. A possible
aveat is that other untested genetic influences could also have
ffected the phenotypic expression of the LAMP-2 mutations.
he potential for de novo mutations in the LAMP-2 gene, as
emonstrated in proband 1’s family, indicates that Danon
ardiomyopathy should be considered even in the absence of a
ositive family history.
The histopathology of the heart explants of all female family
embers in this study was characterized by extensive fibrosis,
ith prominent myocyte vacuolization in the areas of fibrosis.
his “end-stage” pathology overlaps and may mask the charac-
eristic vacuolar changes of Danon disease. These findings may
e similar to HCM patients who develop a “burned-out”
athology (7,8).
Peri-partum cardiomyopathy is defined as the development of
ongestive heart failure with a DCM phenotype of unidentified
ause, leading to a decreased LVEF (45%) in the last month of
regnancy or within 5 months after delivery (9). Two female
embers in these families demonstrate a situation in which Danon
ardiomyopathy presented for the first time in the peri-partum
eriod. Thus, these results suggest that some cases of PPCM may
e LAMP-2 mutations presenting with a DCM phenotype, either
s a coincidence or as the result of the physiologic alterations of
regnancy, triggering the clinical expression of the cardiomyopa-
A
B
C
Figure 1 Genetic Pedigrees of the 3 Study Families
(A) Family of proband 1. (B) Family of proband 2. (C) Family of proband 3. Proban
boxes represent male patients. Solid shapes represent family members with Dano
cardiac health is limited. This subject is presumed to be affected as the result of
Hashes are drawn over family members known to have died from Danon-related co
cytoplasmic vacuolization is demonstrated, with minimal collagen deposition (hem
II-2). Myocyte hypertrophy and fibrosis is demonstrated. In this field, myocyte vacuhy. The absence of pre-excitation in 6 of the 7 female subjects inur study suggests that ECG would not be a reliable screening tool
or the presence of Danon cardiomyopathy. These cases emphasize
he importance of a detailed family history in the evaluation of
oung woman presenting with a DCM phenotype in the peri-
artum period and consideration of testing for LAMP-2 mutations
n this patient population.
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2007;118:295–303.Letters to the Editorhe Role of Omega-3 Fatty
cids in Primary Prevention of
oronary Artery Disease and in
trial Fibrillation Is Controversial
e read with interest a recent review article on the cardiovascular
ffects of omega-3 fatty acids (-3 PUFA) by Lavie et al. (1) and
ish to highlight some of the controversial issues in this review. In
elation to the role of -3 PUFA in primary prevention of
oronary artery disease (CAD), the authors quote 3 studies—the
ART (Diet And Reinfarction Trial) (2), GISSI Prevenzione
Gruppo Italiano per lo Studio della Sopravvivenza nell’ Infarto
iocardico–Prevenzione) study (3), and JELIS (Japan EPA Lipid
ntervention Study) (4)—as supportive evidence for a beneficial
ffect. As discussed further in the same review, the DART and
ISSI Prevenzione studies are secondary prevention studies, and
n the JELIS—which included 14,981 subjects in primary preven-
ion and 3,664 subjects in secondary prevention—major coronary
vents were indeed significantly reduced in the -3 PUFA-treated
ubjects. However, when the groups with and without previous
AD (i.e., primary and secondary prevention cohorts) were
ndividually analyzed, there was no benefit in the primary preven-
ion group. Therefore, the 3 studies quoted by the authors do not
end any supportive evidence to the claim that -3 PUFA are
seful in primary prevention of CAD.
In addition, the authors claim that the most significant antiar-
hythmic effects of -3 PUFA are noted in studies on atrial
brillation (AF) and quote 2 interventional studies (5,6) in
ddition to 1 observational study (7). To our knowledge, there has
een only 1 interventional study published on the effect of -3
UFA on AF after coronary artery bypass graft surgery. This study
y Calò et al. (5) is a relatively small open-label study in 160
atients who received 2 g/day of -3 PUFA for 5 days before
oronary artery bypass surgery. The second study referred to by the
uthors (6) is in fact a systematic review of studies that have
valuated all interventions that might be of benefit in reducing AF
fter coronary artery bypass graft surgery.
We wish to highlight that there were 2 large epidemiological
tudies—the Rotterdam Study (8) quoted by the authors and thessociation between the risk of developing AF and dietary fish
ntake.
Of note, the study by Mozaffarian et al. (7) exclusively looked at
ubjects 65 years of age and could not be extrapolated to the
ntire population at risk of AF, which would include both young
often lone AF) and old (often with underlying structural heart
isease).
The authors have failed to indicate that a recent systematic
eview by Leo´n et al. (10) and a systematic review of the 3 large
tudies on implantable cardioverter-defibrillator population (11)
ave reported no benefit with -3 PUFA therapy on cardiac
rrhythmias. Hence, we believe that the role of -3 PUFA on
rimary prevention of CAD and AF are far from clear as this
eview seems to suggest.
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